DXC Technology Completes the Sale of DXC’s Healthcare Provider Software Business to the Dedalus Group

Rhea-AI Summary

DXC Technology has finalized the sale of its healthcare provider software business to Dedalus Group for approximately $450 million. This divestiture aligns with DXC's strategy to focus on the Enterprise Technology Stack. CEO Mike Salvino stated that the move strengthens DXC's balance sheet and creates value for stakeholders. Dedalus aims to enhance its clinical IT presence and is set to integrate its offerings to improve healthcare outcomes. This transaction marks a significant step in Dedalus's growth strategy initiated four years ago.

Positive

• Received net proceeds of approximately $450 million from the sale.
• Strengthened balance sheet and unlocked value for stakeholders.

Negative

• None.

DXC Technology (NYSE: DXC) today announced that it has completed the sale of DXC’s healthcare provider software business to the privately held Dedalus Group, a leading European healthcare and diagnostic software company, which is creating a stronger global presence in the clinical IT areas of hospital information systems (HIS), primary and social care, integrated care and diagnostics. The transaction was previously announced in July 2020.

The sale of DXC’s healthcare provider software business to Dedalus is consistent with DXC’s strategy and focus on the Enterprise Technology Stack. DXC expects to receive net proceeds of about $450 million from the transaction.

“The completion of the sale of our healthcare provider software business strengthens our balance sheet and unlocks new value for our stakeholders,” said Mike Salvino, President and CEO, DXC. “I would like to thank our people who are moving on to the Dedalus Group for their commitment and contributions over the years and for their focus on our customers during this process.”

“Dedalus’ vision is for a digitally enabled healthcare ecosystem where all stakeholders actively collaborate across the continuum of care to improve each citizen's health outcomes,” said Andrea Fiumicelli, CEO of Dedalus Group. “The acquisition by Dedalus is on par with our growth initiative strategy that began four years ago. Our expanded software solutions enable the integration of processes, workflows and applications in order to improve healthcare outcomes for each individual and for the population as a whole. At the core of our business is a constant focus and commitment to data security and to create and deliver innovation at scale.”

“We have an incredible research and development team and a strong leadership team. Our mission is to innovate,” continued Giorgio Moretti, Chairman of Dedalus Group. “Our expectation in the coming years is that healthcare will embrace new technologies and service paradigms that will transform the experience of care for all citizens and care teams.”

Yann Chareton, Managing Director, Ardian Buyout, concluded, “This deal further enables Dedalus to make a decisive step in its consolidation strategy.”

About DXC Technology

DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to provide services across the Enterprise Technology Stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology.

About Dedalus

Founded in Florence in 1982 by the current Chairman Giorgio Moretti, Dedalus Group is the leading healthcare and diagnostic software provider in Europe and one of the largest in the world. The shareholding structure ensures stability and great financial capacity through the presence of Ardian, the largest private investment company in Europe and the fourth in the world.

Starting in 2016, Dedalus has accelerated its expansion strategy by targeting the growing demand for innovative and comprehensive ICT and Clinical transformation solutions. Today Dedalus has a strong footprint in Germany, Italy, France, UK & Ireland, Northern Europe, Austria, Switzerland, Spain, China, Brazil, Australia, New Zealand and several locations in Latin America, the Middle East and Africa, having a presence in over 40 different countries. Thanks to its undisputed cutting-edge portfolio of leading, new generation solutions, Dedalus covers the whole spectrum of needs for healthcare operators, supporting over 6,000 hospitals and 5,000 laboratories around the world.www.dedalus.com.

About Ardian

Ardian is a world-leading private investment house with assets of US$100bn managed or advised in Europe, the Americas and Asia. The company is majority-owned by its employees. It keeps entrepreneurship at its heart and focuses on delivering excellent investment performance to its global investor base. Through its commitment to shared outcomes for all stakeholders, Ardian’s activities fuel individual, corporate and economic growth around the world. Holding close its core values of excellence, loyalty and entrepreneurship, Ardian maintains a truly global network, with more than 670 employees working from fifteen offices across Europe (Frankfurt, Jersey, London, Luxembourg, Madrid, Milan, Paris and Zurich), the Americas (New York, San Francisco and Santiago) and Asia (Beijing, Singapore, Tokyo and Seoul). It manages funds on behalf of around 1.000 clients through five pillars of investment expertise: Fund of Fu

FAQ

What is the significance of DXC's sale to Dedalus Group?

The sale represents a strategic move for DXC, allowing a focus on the Enterprise Technology Stack while unlocking approximately $450 million in value.

How much did DXC Technology receive from the sale?

DXC Technology expects to receive approximately $450 million in net proceeds from the sale.

When was the sale of DXC's healthcare provider software business announced?

The sale was announced in July 2020 and has recently been completed.

What does this sale mean for Dedalus Group?

The acquisition enhances Dedalus Group's global presence in clinical IT and aligns with its growth strategy focused on healthcare innovation.

What is the focus of DXC Technology following the sale?

Following the sale, DXC Technology aims to concentrate on the Enterprise Technology Stack.